Ongoing research involves the evaluation
of immune checkpoint inhibition in collaboration with the Ludwig / CRI CVC trials network and the pharmaceutical industry.
«The ability to predict progression to stage IV disease is extremely important in light of recent findings that
immune checkpoint inhibition improves OS in stage III melanoma,» the researchers wrote.